Share this article on:

Preserving Treg Function: Beyond mTOR Inhibitors

Adigbli, George MBBS, MSc, MRCS1; Issa, Fadi MRCS, DPhil1

doi: 10.1097/TP.0000000000002042
In View: Game Changer

1 Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, UK.

Received 11 November 2017. Accepted 13 November 2017.

The author declares no conflicts of interest or funding.

Correspondence: Fadi Issa, MRCS, DPhil, Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, UK. (

When the antifungal compound rapamycin was discovered in 1972 within bacteria isolated from soil samples acquired on the South Pacific island of Rapa Nui, its future use in preventing transplant rejection could not have been predicted. As advancing research unearthed the evolutionarily conserved signal transduction pathway mTOR (mechanistic target of rapamycin),1 an understanding of the role of rapamycin in abrogating T-cell activation developed. There has since been much interest in detailing the potential of this class of immunosuppressant in modulating or enhancing regulatory T (Treg) cell function.2,3 An additional interest has been the anticancer potential of mTOR inhibitors, although these effects are not entirely clear or consistent.4-7 During the late 1980s and early 1990s, another receptor-signaling pathway, exclusive to resting Treg cells and activated T cells bearing the OX40 (CD134) receptor was also discovered.8 OX40 is enriched at sites of autoimmune inflammation9,10 and is found on the surface of circulating lymphocytes in systemic autoimmune diseases. Once ligated, OX40 signaling promotes the development of a cytokine-producing effector T (Teff) cells and prolongs the survival of memory T (Tmem) cells. Blockade or deficiency of OX40 has been shown to effectively attenuate autoimmune pathology.11,12 In vivo studies have demonstrated that OX40 ligand (OX40L) blockade can abrogate autoimmunity,11 potentially representing a more effective target than its receptor.13 In transplantation, blockade of OX40 effectively targets both CD4+ and CD8+ T cells to prevent rejection.14

Leslie Kean’s group has contributed extensively to the field of transplant tolerance, with a specific focus on the summative benefits of combinatorial therapies targeting T cell costimulatory and coinhibitory pathways. Having previously published promising results in their nonhuman primate (NHP) transplant model,15-21 the group is currently involved in clinical trials assessing the efficacy of CTLA4-Ig therapy to prevent severe graft versus host disease (GVHD); moreover, current trials include an anti-CD28 Fab22 for the treatment of rheumatoid arthritis. There is certainly a strong argument for using combinatorial therapies to manipulate lymphocyte signaling pathways to simultaneously tilt the immune balance toward allograft tolerance in both Treg cell and Teff cell compartments.22

In their recent study published in Science Translational Medicine,23 the authors aimed to identify an immunoprophylactic therapy that can synergize with the protolerogenic capabilities of sirolimus and in doing so highlighted the ability of OX40-OX40L blockade to control Tmem and Teff function while preserving the homeostasis and function of Treg. Using an NHP model of GVHD, they demonstrated increased expression of OX40L on lymph node-derived myeloid dendritic cells after allotransplantation in the absence of immunoprophylaxis. Moreover, they observed the OX40-encoding transcript TNFRSF4 in T cells after allotransplantation when using sirolimus. Based on those observations, they assessed the effects of OX40-OX40L blockade using a monoclonal anti-OX40L antibody (KY1005) with or without sirolimus in their high-risk NHP allogeneic GVHD model. KY1005 monotherapy reduced the rates of proliferating T cells and OX40+ CD4+ conventional T cells (predominantly central memory [TCM]) without impacting the proportion of Treg while modestly extended recipient survival (+11.5 days compared with untreated controls). Anti-OX40L treatment also reduced CD4+ T-cell expression of IL-17A, the hallmark cytokine of the Th17 profile typically associated with breakthrough acute GVHD (aGVHD).

The response to combined anti-OX40L and mTOR inhibition was much more effective: GVHD-free survival lasted the full 100-day experimental period with negligible clinical disease scores recorded.

Additionally, all recipients demonstrated effective donor engraftment with robust T-cell chimerism. Allospecific T-cell activation was controlled with significantly reduced CD4+ and CD8+ proliferation, decreased proportions (however, not numbers) of CD4+ TCM cells, and enhanced reconstitution of Treg and naive CD4+ T cells. Recipients that received the combinatorial treatment had distinct immunological transcriptome profiles, suggesting a unique synergistic effect of the combined therapies.

This study impressively demonstrates how the simultaneous blockade of synergistic inflammatory pathways can enhance efficacy. The mTOR pathway is known to affect T-cell function in several ways: (i) impacting T-cell proliferation in response to antigen stimulation (via IL-2); (ii) switching energy generation (known as the Warburg effect24) required during the transition of T cells from a resting state to a state of activation, differentiation, or proliferation25; and (iii) as a critical regulator of FoxP3 expression and Treg development.26 Blocking these effects while concurrently antagonizing a costimulatory signal essential for full T-cell activation has provided a therapy capable of delivering long-term allograft tolerance while preventing breakthrough aGVHD. This approach provided a significant advantage compared with other costimulation modulators, such as belatacept,27 while avoiding side effects notoriously associated with first-line calcineurin inhibitors.

Indeed, enhanced reconstitution of Tregs concurrent with reduced donor-specific Teffs is a highly attractive therapy based on the outcome of this study. In addition to being of relevance in preventing aGVHD, an enriched Treg pool has been frequently documented as key to providing long term protection against chronic allograft rejection in animal models.28-30 It will be interesting to test the durability of Treg reconstitution with a combinatorial treatment of KY1005 and mTOR inhibition as OX40 signaling is said to maintain T-cell survival.31

The complex relationship between OX40 signaling and Treg function has been comprehensively documented, yet there is no clear consensus on whether OX40 enhances or inhibits suppressive capacity. Studies have shown that OX40-deficient Tregs display an impaired ability to control inflammation in vivo.32 In addition, within the “right” cytokine milieu, OX40 engagement expands Tregs33,34 while inducing long-term allograft survival.35 Conversely, OX40 stimulation has been shown to profoundly inhibit FoxP3 expression.36 Moreover, antibody-mediated activation of OX40 has been shown to deplete Tregs while enhancing the antitumor immune response.37 In a model of skin transplantation, OX40 blockade at the time of exposure to alloantigen attenuated graft rejection.38 This effect had been linked to both enhanced suppressive potency and prolonged survival of Tregs upon blockade of OX40-OX40L signaling, findings that are in accordance with the present study (Figure 1). Thus, supported by the Science Translational Medicine publication and by the work of others, OX40L blockade may augment tolerance.27



Transduction of reverse signals from OX40 to OX40L has been shown to produce enhanced maturation and cytokine production in human dendritic cells39 as well as proliferation and IgG secretion by activated B cells.40,41 In turn, OX40L blockade has recently demonstrated suppressive effects mediated in part by inhibiting reverse-signaling on activated APCs and mesenchymal cells42 (Figure 1). Considering the importance of the cytokine milieu for OX40+ Tregs, and to obtain a greater understanding of the mechanisms underlying the findings reported, it would be intriguing to identify how far the effects conferred by OX40L blockade are linked with reverse signaling to APC’s and subsequent alterations of their phenotype and cytokine profiles. It should be noted that because there is no leukemia model in NHPs, evaluation of the graft-versus-leukemia response after hematopoeitic stem cell transplantation has not been possible. It will therefore be critically important for clinical trials to have robust cessation criteria to safeguard against the risk of relapse.

The exciting findings of this innovative study address several problems with current established immunosuppressive therapies and provide a strong basis for clinical translation. The reported results are promising because the simultaneous targeting of costimulatory and mTOR pathways target Teff cells and Treg cells differentially, with the potential to tilt the balance toward allograft tolerance.

Back to Top | Article Outline


1. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168:960–976.
2. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4 + CD25 + FoxP3+ regulatory T cells. Blood. 2005;105:4743–4748.
3. Chapman NM, Chi H. mTOR signaling, Tregs and immune modulation. Immunotherapy. 2014;6:1295–1311.
4. de Fijter JW. Cancer and mTOR inhibitors in transplant recipients. Transplantation. 2017;101:45–55.
5. Geissler E, Schnitzbauer AA, Zülke C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation. 2016;100:116–125.
6. Geissler EK. Post-transplantation malignancies: here today, gone tomorrow? Nat Rev Clin Oncol. 2015;12:705–717.
7. Opelz G, Unterrainer C, Susal C, et al. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients. Nephrol Dial Transplant. 2016;31:1360–1367.
8. Kinnear G, Jones ND, Wood KJ. Costimulation blockade: current perspectives and implications for therapy. Transplantation. 2013;95:527–535.
9. Stüber E, Büschenfeld A, Lüttges J, et al. The expression of OX40 in immunologically mediated diseases of the gastrointestinal tract (celiac disease, Crohn's disease, ulcerative colitis). Eur J Clin Invest. 2000;30:594–599.
10. Giacomelli R, Passacantando A, Perricone R, et al. T lymphocytes in the synovial fluid of patients with active rheumatoid arthritis display CD134-OX40 surface antigen. Clin Exp Rheumatol. 2001;19:317–320.
11. Gaspal F, Withers D, Saini M, et al. Abrogation of CD30 and OX40 signals prevents autoimmune disease in FoxP3-deficient mice. J Exp Med. 2011;208:1579–1584.
12. Higgins LM, McDonald SA, Whittle N, et al. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J Immunol. 1999;162:486–493.
13. Gwyer Findlay E, Danks L, Madden J, et al. OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis. Proc Natl Acad Sci U S A. 2014;111:2289–2294.
14. Kinnear G, Wood KJ, Marshall D, et al. Anti-OX40 prevents effector T-cell accumulation and CD8+ T-cell mediated skin allograft rejection. Transplantation. 2010;90:1265–1271.
15. Mary C, Coulon F, Poirier N, et al. Antagonist properties of monoclonal antibodies targeting human CD28. MAbs. 2013;5:47–55.
16. Poirier N, Mary C, Dilek N, et al. Preclinical efficacy and immunological safety of fr104, an antagonist anti‐cd28 monovalent Fab′ antibody. Am J Transplant. 2012;12:2630–2640.
17. Poirier N, Dilek N, Mary C, et al. FR104, an antagonist anti-CD28 monovalent fab'antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft. Am J Transplant. 2015;15:88–100.
18. Vierboom MP, Breedveld E, Kap YS, et al. Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis. Clin Exp Immunol. 2016;183:405–418.
19. Haanstra KG, Dijkman K, Bashir N, et al. Selective blockade of CD28-mediated T cell costimulation protects rhesus monkeys against acute fatal experimental autoimmune encephalomyelitis. J Immunol. 2015;194:1454–1466.
20. Ville S, Poirier N, Branchereau J, et al. Anti-CD28 antibody and belatacept exert differential effects on mechanisms of renal allograft rejection. J Am Soc Nephrol. 2016;27:3577–3588.
21. Hippen KL, Watkins B, Tkachev V, et al. Preclinical testing of antihuman CD28 Fab′ antibody in a novel nonhuman primate small animal rodent model of xenogenic graft-versus-host disease. Transplantation. 2016;100:2630–2639.
22. Kean LS, Turka LA, Blazar BR. Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy. Immunol Rev. 2017;276:192–212.
23. Tkachev V, Furlan SN, Watkins B, et al. Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant. Sci Transl Med. 2017;20:9(408).
24. Warburg O. On respiratory impairment in cancer cells. Science. 1956;124:269–270.
25. Cobbold SP. The mTOR pathway and integrating immune regulation. Immunology. 2013;140:391–398 .
26. Delgoffe GM, Kole TP, Zheng Y, et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity. 2009;30:832–844.
27. Kitchens WH, Dong Y, Mathews DV, et al. Interruption of OX40L signaling prevents costimulation blockade-resistant allograft rejection. JCI insight. 2017;2:e90317.
28. Pilat N, Farkas AM, Mahr B, et al. T-regulatory cell treatment prevents chronic rejection of heart allografts in a murine mixed chimerism model. J Heart Lung Transplant. 2014;33:429–437.
29. Joffre O, Santolaria T, Calise D, et al. Prevention of acute and chronic allograft rejection with CD4 + CD25 + Foxp3+ regulatory T lymphocytes. Nat Med. 2008;14:88–92.
30. Nadig SN, Wieckiewicz J, Wu DC, et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med. 2010;16:809–813.
31. Rogers PR, Song J, Gramaglia I, et al. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity. 2001;15:445–455.
32. Griseri T, Asquith M, Thompson C, et al. OX40 is required for regulatory T cell–mediated control of colitis. J Exp Med. 207:699–709.
33. Hippen KL, Harker-Murray P, Porter SB, et al. Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood. 2008;112:2847–2857.
34. Ruby CE, Yates MA, Hirschhorn-Cymerman D, et al. Cutting edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. J Immunol. 2009;183:4853–4857.
35. Xiao X, Gong W, Demirci G, et al. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. J Immunol. 2012;188:892–901.
36. Vu MD, Xiao X, Gao W, et al. OX40 costimulation turns off Foxp3(+) Tregs. Blood. 2007;110:2501–2510.
37. Bulliard Y, Jolicoeur R, Zhang J, et al. OX40 engagement depletes intratumoral Tregs via activating Fc[gamma]Rs, leading to antitumor efficacy. Immunol Cell Biol. 2014;92:475–480.
38. Kinnear G, Wood KJ, Fallah-Arani F, et al. A diametric role for OX40 in the response of effector/memory CD4+ T cells and regulatory T cells to alloantigen. J Immunol. 2013;191:1465–1475.
39. Ohshima Y, Tanaka Y, Tozawa H, et al. Expression and function of OX40 ligand on human dendritic cells. J Immunol. 1997;159:3838–3848.
40. Stüber E, Neurath M, Calderhead D, et al. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity. 1995;2:507–521.
41. Ishii N, Takahashi T, Soroosh P, et al. OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology. Adv Immunol. 2010;105:63–98.
42. Elhai M, Avouac J, Hoffmann-Vold AM, et al. OX40L blockade protects against inflammation-driven fibrosis. Proc Natl Acad Sci U S A. 2016;113:E3901–E3910.
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.